The Impax/Shire AdderallXR trial is due to commence on 23rd February. This is a huge trial for Shire. If they lose you wouldn't want to be long thats for sure. Its a risky time to be holding Shire. You could make or lose a lot of money depending on the verdict. And then once that trial is over the Barr one will commence so you've got to go through the whole thing again. And then they'll be the appeals. I'm glad I'm out for the time-being.
The post about the impax trial doesn't bother me. The fda gave shire exclusivity up until april no matter how the trial goes.
We expect to file for approval for both our new add products this quarter. 465 is a longer acting version of adderalxr and will be marketed to adults and teens who need a longer lasting product. Our 503 product is a non narcotic that should find a market with younger pts. The new river product is still a stimulant regardless of it's different properties to reduce over dose and abuse. Physicians and psychiatrists will still look for a non narcotic product to use and strattera as everyone knows has some side effect issues. In fact strattera sales declined in a year when add scripts increased 17% overall.
Adderallxr sp465 Sp503 Daytrana NR104
Pretty darned nice portfolio of products to sell in a $3B market that expects to grow about 8-10% a year.